Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm

Eddy S. Yang, Kerry L. Burnstein

Journal of Biological Chemistry · 2003 · 152 citations · 53 references

DOIFull text

Open access

Concepts

Abstract

1,25-(OH)2 vitamin D3 (1,25-(OH)2D3) exerts antiproliferative effects via cell cycle regulation in a variety of tumor cells, including prostate. We have previously shown that in the human prostate cancer cell line LN-CaP, 1,25-(OH)2D3 mediates an increase in cyclin-dependent kinase inhibitor p27Kip1 levels, inhibition of cyclin-dependent kinase 2 (Cdk2) activity, hypophosphorylation of retinoblastoma protein, and accumulation of cells in G1. In this study, we investigated the mechanism whereby 1,25-(OH)2D3 increases p27 levels. 1,25-(OH)2D3 had no effect on p27 mRNA levels or on the regulation of a 3.5-kb fragment of the p27 promoter. The rate of p27 protein synthesis was not affected by 1,25-(OH)2D3 as measured by luciferase activity driven by the 5′- and 3′-untranslated regions of p27 that regulate p27 protein synthesis. Pulse-chase analysis of 35S-labeled p27 revealed an increased p27 protein half-life with 1,25-(OH)2D3 treatment. Because Cdk2-mediated phosphorylation of p27 at Thr187 targets p27 for Skp2-mediated degradation, we examined the phosphorylation status of p27 in 1,25-(OH)2D3-treated cells. 1,25-(OH)2D3 decreased levels of Thr187 phosphorylated p27, consistent with inhibition of Thr187 phosphorylation-dependent p27 degradation. In addition, 1,25-(OH)2D3 reduced Skp2 protein levels in LNCaP cells. Cdk2 is activated in the nucleus by Cdk-activating kinase through Thr160 phosphorylation and by cdc25A phosphatase via Thr14 and Tyr15 dephosphorylation. Interestingly, 1,25-(OH)2D3 decreased nuclear Cdk2 levels as assessed by subcellular fractionation and confocal microscopy. Inhibition of Cdk2 by 1,25-(OH)2D3 may thus involve two mechanisms: 1) reduced nuclear Cdk2 available for cyclin binding and activation and 2) impairment of cyclin E-Cdk2-dependent p27 degradation through cytoplasmic mislocalization of Cdk2. These data suggest that Cdk2 mislocalization is central to the antiproliferative effects of 1,25-(OH)2D3. 1,25-(OH)2 vitamin D3 (1,25-(OH)2D3) exerts antiproliferative effects via cell cycle regulation in a variety of tumor cells, including prostate. We have previously shown that in the human prostate cancer cell line LN-CaP, 1,25-(OH)2D3 mediates an increase in cyclin-dependent kinase inhibitor p27Kip1 levels, inhibition of cyclin-dependent kinase 2 (Cdk2) activity, hypophosphorylation of retinoblastoma protein, and accumulation of cells in G1. In this study, we investigated the mechanism whereby 1,25-(OH)2D3 increases p27 levels. 1,25-(OH)2D3 had no effect on p27 mRNA levels or on the regulation of a 3.5-kb fragment of the p27 promoter. The rate of p27 protein synthesis was not affected by 1,25-(OH)2D3 as measured by luciferase activity driven by the 5′- and 3′-untranslated regions of p27 that regulate p27 protein synthesis. Pulse-chase analysis of 35S-labeled p27 revealed an increased p27 protein half-life with 1,25-(OH)2D3 treatment. Because Cdk2-mediated phosphorylation of p27 at Thr187 targets p27 for Skp2-mediated degradation, we examined the phosphorylation status of p27 in 1,25-(OH)2D3-treated cells. 1,25-(OH)2D3 decreased levels of Thr187 phosphorylated p27, consistent with inhibition of Thr187 phosphorylation-dependent p27 degradation. In addition, 1,25-(OH)2D3 reduced Skp2 protein levels in LNCaP cells. Cdk2 is activated in the nucleus by Cdk-activating kinase through Thr160 phosphorylation and by cdc25A phosphatase via Thr14 and Tyr15 dephosphorylation. Interestingly, 1,25-(OH)2D3 decreased nuclear Cdk2 levels as assessed by subcellular fractionation and confocal microscopy. Inhibition of Cdk2 by 1,25-(OH)2D3 may thus involve two mechanisms: 1) reduced nuclear Cdk2 available for cyclin binding and activation and 2) impairment of cyclin E-Cdk2-dependent p27 degradation through cytoplasmic mislocalization of Cdk2. These data suggest that Cdk2 mislocalization is central to the antiproliferative effects of 1,25-(OH)2D3. 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) 1The abbreviations used are: 1,25-(OH)2D31,25-dihydroxyvitamin D3VDRvitamin D receptorCKIcyclin-dependent kinase inhibitorCdk2cyclin-dependent kinase 2UTRuntranslated regionPBSphosphate-buffered salineCAKCdk-activating kinase. exerts important effects on cellular proliferation and differentiation (1Pols H.A. Birkenhager J.C. Foekens J.A. van Leeuwen J.P. J. Steroid Biochem. Mol. Biol. 1990; 37: 873-876Crossref PubMed Scopus (102) Google Scholar, 2Bikle D.D. Endocr. Rev. 1992; 13: 765-784PubMed Google Scholar, 3Walters M.R. Endocr. Rev. 1992; 13: 719-764Crossref PubMed Google Scholar, 4Feldman D. Glorieux F.H. Pike J.W. Vitamin D. Academic Press, San Diego, CA1997: 1089-1105Google Scholar). 1,25-(OH)2D3 activates the vitamin D receptor (VDR), a ligand-dependent transcription factor that binds cis-acting DNA sequences known as vitamin D response elements (5Glass C.K. Endocr. Rev. 1994; 15: 391-407PubMed Google Scholar). Several established human prostate cancer cell lines, as well as primary cultures of benign and cancerous prostatic tissue, express functional VDRs and are growth inhibited by 1,25-(OH)2D3 (6Miller G.J. Stapleton G.E. Ferrara J.A. Lucia M.S. Pfister S. Hedlund T.E. Upadhya P. Cancer Res. 1992; 52: 515-520PubMed Google Scholar, 7Skowronski R.J. Peehl D.M. Feldman D. Endocrinology. 1993; 132: 1952-1960Crossref PubMed Google Scholar, 8Schwartz G.G. Oeler T.A. Uskokovic M.R. Bahnson R.R. Anticancer Res. 1994; 14: 1077-1081PubMed Google Scholar, 9Miller G.J. Stapleton G.E. Hedlund T.E. Moffatt K.A. Clin. Cancer Res. 1995; 1: 997-1003PubMed Google Scholar, 10Blutt S.E. Allegretto E.A. Pike J.W. Weigel N.L. Endocrinology. 1997; 138: 1491-1497Crossref PubMed Scopus (191) Google Scholar, 11Zhuang S.-H. Schwartz G.G. Cameron D. Burnstein K.L. Mol. Cell. Endocrinol. 1997; 126: 83-90Crossref PubMed Scopus (115) Google Scholar, 12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar). 1,25-dihydroxyvitamin D3 vitamin D receptor cyclin-dependent kinase inhibitor cyclin-dependent kinase 2 untranslated region phosphate-buffered saline Cdk-activating kinase. Our previous studies established that the initial growth inhibition of LNCaP and its androgen-independent derivative LNCaP-104R1 by 1,25-(OH)2D3 correlates with an increase in the levels of the cyclin-dependent kinase inhibitors (CKIs) p21WAF1,CIP1 and p27Kip1, a profound decrease in cyclin-dependent kinase 2 (Cdk2) activity, hypophosphorylation of pRb, and accumulation of cells in the G1 phase of the cell cycle (12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar, 13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar). 1,25-(OH)2D3 also decreased transcriptional activity of the E2F transcription factor family, which regulates the expression of genes necessary for S phase entry (12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar). The CKI p27 appears to play a more central role than p21 in growth inhibition mediated by 1,25-(OH)2D3 and its analogs (13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar, 14Campbell M.J. Elstner E. Holden S. Uskokovic M. Koeffler H.P. J. Mol. Endocrinol. 1997; 19: 15-27Crossref PubMed Scopus (181) Google Scholar). In several prostate cancer cell lines, 1,25-(OH)2D3 treatment results in persistent up-regulation of p27, whereas p21 is only induced transiently (12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar, 13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar, 14Campbell M.J. Elstner E. Holden S. Uskokovic M. Koeffler H.P. J. Mol. Endocrinol. 1997; 19: 15-27Crossref PubMed Scopus (181) Google Scholar). In addition, 1,25-(OH)2D3-mediated growth inhibition of the androgen-independent LNCaP-derivative LNCaP-104R1 cells occurs without induction of p21 (13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar). Loss of p27 expression correlates with prostate cancer recurrence, a more aggressive phenotype, and decreased patient prognosis and survival (15Guo Y. Sklar G.N. Borkowski A. Kyprianou N. Clin. Cancer Res. 1997; 3: 2269-2274PubMed Google Scholar, 16Cote R.J. Shi Y. Groshen S. Feng A.C. Cordon-Cardo C. Skinner D. Lieskovosky G. J. Nat. Cancer Inst. 1998; 90: 916-920Crossref PubMed Scopus (188) Google Scholar, 17Tsihlias J. Kapusta L.R. DeBoer G. Morava-Protzner I. Zbieranowski I. Bhattacharya N. Catzavelos G.C. Klotz L.H. Slingerland J.M. Cancer Res. 1998; 58: 542-548PubMed Google Scholar, 18Yang R.M. Naitoh J. Murphy M. Wang H.J. Phillipson J. deKernion J.B. Loda M. Reiter R.E. J. Urology. 1998; 159: 941-945Crossref PubMed Scopus (277) Google Scholar, 19Fernandez P.L. Arce Y. Farre X. Martinez A. Nadal A. Rey M.J. Peiro N. Campo E. Cardesa A. J. Pathol. 1999; 187: 563-566Crossref PubMed Scopus (47) Google Scholar, 20Cheng L. Lloyd R.V. Weaver A.L. Pisansky T.M. Cheville J.C. Ramnani D.M. Leibovich B.C. Blute M.L. Zincke H. Bostwick D.G. Clin. Cancer Res. 2000; 6: 1896-1899PubMed Google Scholar, 21Yang G. Ayala G. De Marzo A. Tian W. Frolov A. Wheeler T.M. Thompson T.C. Harper J.W. Clin. Cancer Res. 2002; 8: 3419-3426PubMed Google Scholar, 22Halvorsen O.J. Haukaas S.A. Akslen L.A. Clin. Cancer Res. 2003; 9: 1474-1479PubMed Google Scholar). Reduced p27 protein, however, is not the result of p27 gene mutations, which are quite rare in cancers (23Kawamata N. Morosetti R. Miller C.W. Park D. Spirin K.S. Nakamaki T. Takeuchi S. Hatta Y. Simpson J. Wilcyznski S. Cancer Res. 1995; 55: 2266-2269PubMed Google Scholar, 24Ponce-Castaneda M.V. Lee M.H. Latres E. Polyak K. Lacombe L. Montgomery K. Mathew S. Krauter K. Sheinfeld J. Massague J. Cancer Res. 1995; 55: 1211-1214PubMed Google Scholar, 25Ferrando M. G. C. PubMed Scopus Google Scholar). of results in p27 and decreased p27 levels M. S. Y. K. S. Y. 1997; 15: PubMed Scopus Google Scholar, D. H. R. D. Cancer Res. 1999; Google Scholar, A. Slingerland J.M. J. Biol. PubMed Scopus Google Scholar, R. N. H. H. H. Biol. PubMed Scopus Google Scholar). the whereby p27 levels are may targets for Because of the role of p27 in prostate cancer we investigated the mechanism of 1,25-(OH)2D3 regulation of this CKI in LNCaP cells. p27 is an important of the G1 to S phase p27 binds and cyclin and regulates S phase cellular p27 levels mechanism to this regulation p27 M. P. G. M. 1995; PubMed Scopus Google Scholar, L. PubMed Scopus Google Scholar). for this phosphorylation at Thr187 by Cdk2 and of by the J. Kapusta L.R. DeBoer G. Morava-Protzner I. Zbieranowski I. Bhattacharya N. Catzavelos G.C. Klotz L.H. Slingerland J.M. Cancer Res. 1998; 58: 542-548PubMed Google Scholar, R.J. M. M. J.M. 1997; PubMed Scopus Google Scholar, J. S. J. 1997; PubMed Scopus Google Scholar, A. E. A.C. A. M. 1999; 13: PubMed Scopus Google Scholar, Lee H. H. Biol. 1999; 9: PubMed Scopus Google Scholar, J.M. M. J. Cell. 2000; PubMed Scopus Google Scholar). studies have revealed a for p27 degradation at the G1 phase of the cell cycle that is of Thr187 phosphorylation T. T. K. K. S. J. Biol. PubMed Scopus Google Scholar, H. S. K. J.M. PubMed Scopus Google Scholar, R. S. A. R. L. Slingerland J.M. Mol. Biol. Cell. 2003; 14: PubMed Scopus Google Scholar). not well this is to activated by G1 to Cdk2 initial phase of p27 degradation Cdk2 which results in p27 degradation in G1 and entry S this the is of Thr187 phosphorylation and may T. T. K. K. S. J. Biol. PubMed Scopus Google Scholar, H. S. K. J.M. PubMed Scopus Google Scholar, R. S. A. R. L. Slingerland J.M. Mol. Biol. Cell. 2003; 14: PubMed Scopus Google Scholar). The of this for p27 degradation to also for transcriptional M. Lee M. M. PubMed Scopus Google Scholar, T. J. T. J. Biol. 1999; PubMed Scopus Google and L. PubMed Scopus Google Scholar, H. M. H. A. J. Biol. 1997; PubMed Scopus Google Scholar, S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google regulation of of p27 mRNA is by the transcription factor Wang K. S. A. G.E. J. Biol. 2000; PubMed Scopus Google Scholar, 2000; PubMed Scopus Google Scholar). These transcription by the growth which is in including prostate D. H. R. D. Cancer Res. 1999; Google Scholar). In addition, 1,25-(OH)2D3 the p27 by the binding of and transcription to the p27 T. J. T. J. Biol. 1999; PubMed Scopus Google Scholar). The region of the p27 mRNA regulates the of In cells, p27 is an decrease in the synthesis of L. PubMed Scopus Google Scholar, H. M. H. A. J. Biol. 1997; PubMed Scopus Google Scholar, S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google Scholar). The of of the mRNA by the factor factor activity is by in Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar). In the of this is decreased through of factor The of p27, however, an entry which of is by binding of a of the of and binding of nuclear and in mRNA and to the of p27 H. M. H. A. J. Biol. 1997; PubMed Scopus Google Scholar, S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google Scholar, M. L. 2002; PubMed Scopus Google Scholar). the mechanism of 1,25-(OH)2D3-mediated increase in p27 protein levels, we investigated 1,25-(OH)2D3 regulation of p27 and degradation in LNCaP cells. The 1,25-(OH)2D3-mediated increase in p27 was via an increase in p27 protein 1,25-(OH)2D3 treatment decreased Thr187 phosphorylation of p27, a phosphorylation that targets p27 for Skp2-mediated J.M. M. J. Cell. 2000; PubMed Scopus Google Scholar). In addition, 1,25-(OH)2D3 decreased the nuclear of the kinase that p27 at p27 up-regulation by 1,25-(OH)2D3 results increased p27 protein half-life via decreased Thr187 1,25-(OH)2D3-mediated in nuclear Cdk2 may cyclin and Cdk2 activity of reduced nuclear Cdk2 available for cyclin Cdk2 mislocalization also to reduced Thr187 phosphorylation of a of growth regulation by 1,25-(OH)2D3 may the of 1,25-(OH)2D3 to decrease the nuclear of activation of this kinase. and and was 1,25-(OH)2D3 was was p27, protein and and with and by of of cells and in with and of the cultures at in a of cells with or the treatment the with and the cells for was by a the cells and was by and and T. J. T. J. Biol. 1999; PubMed Scopus Google the of of The and S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google by Cancer luciferase the cells with of and of and with or 1,25-(OH)2D3 or for the the treatment the cell and luciferase activity was measured to for the cells with or 1,25-(OH)2D3 for the treatment the was with and for the cells for with of the the cells for and with and the the cells in with of with protein with of p27 and at The with and of of protein for at with with by in of The to to and to cells with or for and in The protein by the to the of cell to and to The for the at in in by with the primary for the in in was used at p27 and Cdk2 used at the with and the the the In Cdk2 cells at with or 1,25-(OH)2D3. the treatment the cells in and in of the inhibitor and The protein of the as of with of Cdk2 or cyclin for at this the with of for at with and with kinase in of kinase of and of for at The by the of of the to and to a was by the the was to for Cdk2 and cyclin E. cells with 1,25-(OH)2D3 or for the treatment the cells in and in 2 and and The for at at and the was The nuclear was by of the in The protein of as of and nuclear to and to The for of p27, fractionation and on the cells with or for the treatment the cells in in for the cells in for The cells for with in and in and for with and the with for and on in The confocal and data The data via a or a analysis of by a for San Diego, confocal the cells and cells the cells and cells analysis was an 1,25-(OH)2 Vitamin D3 the or of previously that 1,25-(OH)2D3 the growth of the LNCaP prostate cancer cell line S.-H. Schwartz G.G. Cameron D. Burnstein K.L. Mol. Cell. Endocrinol. 1997; 126: 83-90Crossref PubMed Scopus (115) Google Scholar, 12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar). in 1,25-(OH)2D3-treated LNCaP cells was decreased of decrease in proliferation by 1,25-(OH)2D3 is with an increased of LNCaP cells in G1 and a decrease in S and with inhibition of G1 to S 1,25-(OH)2D3 increases the levels of the CKI p27Kip1, the of this CKI with and Cdk2 activity in LNCaP cells 12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar, 13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar, 14Campbell M.J. Elstner E. Holden S. Uskokovic M. Koeffler H.P. J. Mol. Endocrinol. 1997; 19: 15-27Crossref PubMed Scopus (181) Google and The mechanism of 1,25-(OH)2D3-mediated up-regulation of p27, however, is not 1,25-(OH)2D3 regulates p27 at the transcriptional we a gene in which the luciferase is driven by a 3.5-kb fragment of the p27 T. J. T. J. Biol. 1999; PubMed Scopus Google Scholar). was previously shown that 1,25-(OH)2D3 activates this in cells the of vitamin D response elements in the p27 T. J. T. J. Biol. 1999; PubMed Scopus Google Scholar). of LNCaP cells luciferase activity, 1,25-(OH)2D3 not increase luciferase activity driven by this fragment of the p27 The to p27 activity 1,25-(OH)2D3 treatment the in which p27 protein is 13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google and and analysis this no in p27 mRNA levels in response to 1,25-(OH)2D3 not These data that 1,25-(OH)2D3-mediated up-regulation of p27 protein was not to increased p27 transcription or increased p27 mRNA D not increase p27 protein LNCaP cells with or luciferase activity by the 5′- and 3′-untranslated regions of and with or 1,25-(OH)2D3. The cells and luciferase activity was a cells also to a known of p27 protein synthesis. of LNCaP cells with or 1,25-(OH)2D3 or to for The cell to analysis with was used as a The data in two in activity in cells was cells vitamin D levels in LNCaP cells with or 1,25-(OH)2D3. the treatment the and to analysis with to Thr187 phosphorylated p27, p27, and and or two The data the levels as of analysis was an vitamin The rate of p27 is by the 5′- and of the p27 mRNA L. PubMed Scopus Google Scholar, H. M. H. A. J. Biol. 1997; PubMed Scopus Google Scholar, S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google Scholar). a gene in which the luciferase gene is by the 5′- and of p27, we assessed 1,25-(OH)2D3 the rate of p27 1,25-(OH)2D3 not by the 5′- and of p27, whereas a known of p27 protein synthesis H. M. H. A. J. Biol. 1997; PubMed Scopus Google Scholar, S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google a for p27 protein cell to analysis for p27, and cell cycle was a of 1,25-(OH)2D3 induction of driven by the p27 protein was increased in 1,25-(OH)2D3-treated and in cells In addition, of 1,25-(OH)2D3 LNCaP cells in G1 not These data are consistent with 1,25-(OH)2D3-mediated increases in p27 protein levels through a mechanism than increased 1,25-(OH)2 Vitamin D3 p27 via Cdk2 of 1,25-(OH)2D3-mediated increases in p27 protein are to decreased p27 degradation, analysis was in 1,25-(OH)2D3 increased the half-life of p27 protein in cells to than in 1,25-(OH)2D3-treated cells. The of p27 in and cells are with in studies for growth and cells L. PubMed Scopus Google Scholar, M. E. Pfister G. W. W. P. 37: PubMed Scopus Google Scholar). cells to S p27 levels is in by phosphorylation of p27 at Thr187 by cyclin phosphorylation targets p27 for degradation by its by the the 1,25-(OH)2D3-mediated regulation of p27 the levels of in 1,25-(OH)2D3 treatment at and results in decreased whereas p27 was increased at two These results that 1,25-(OH)2D3-mediated of p27 in LNCaP cells was to decreased of p27 for 1,25-(OH)2 Vitamin D3 in Skp2 Thr187 phosphorylation-dependent p27 was that the vitamin D mediates up-regulation of p27 in and cells via of Skp2 and decreased of p27 with which to p27 R. Wang Miller Endocrinology. 2003; PubMed Scopus Google Scholar). We that Skp2 protein levels decreased by 1,25-(OH)2D3 and of treatment Because Skp2 is as cells the cell cycle C. H. M. M. M. W. J. 2000; 19: PubMed Scopus Google the of Skp2 may the result of growth by 1,25-(OH)2D3. we examined a more of p27 degradation, the and activation of Cdk2. 1,25-(OH)2 Vitamin D3 of p27 with of G1 phase of p27 degradation that increases at the G1 to S phase is on Cdk2 phosphorylation of p27 at Cdk2 to Cdk2 the nucleus to phosphorylated by Cdk-activating kinase and to by the phosphatase Cdk2 at and Cdk2 at Thr14 and Tyr15 C. J. Biol. PubMed Scopus Google Scholar, C. J. Biol. 2002; PubMed Scopus Google Scholar). of Cdk2 is a 1,25-(OH)2D3-mediated effects on p27 degradation involve regulation of Cdk2 and 1,25-(OH)2D3-treated LNCaP cells to of Cdk2. of cells confocal revealed decreased Cdk2 nuclear and of 1,25-(OH)2D3 treatment fractionation and analysis this to cytoplasmic Cdk2 These results suggest that 1,25-(OH)2D3-mediated growth inhibition decreased Cdk2 nuclear which to the inhibition of activity and the impairment of p27 D nuclear levels of LNCaP cells with or 1,25-(OH)2D3 for The cells nuclear and to analysis with to Cdk2 or was used as a the of the analysis for the protein was The data are of of Cdk2 levels was via analysis was an cells. vitamin 1,25-(OH)2D3 shown to decrease the growth of including prostate. The mechanism of the initial growth is by the G1 to S phase in the cell cycle S.E. Allegretto E.A. Pike J.W. Weigel N.L. Endocrinology. 1997; 138: 1491-1497Crossref PubMed Scopus (191) Google Scholar, 12Zhuang S.-H. Burnstein K.L. Endocrinology. 1998; 139: 1197-1207Crossref PubMed Scopus (203) Google Scholar, 13Yang E.S. Maiorino C.A. Roos B.A. Knight S.R. Burnstein K.L. Mol. Cell. Endocrinol. 2002; 186: 69-79Crossref PubMed Scopus (40) Google Scholar, 14Campbell M.J. Elstner E. Holden S. Uskokovic M. Koeffler H.P. J. Mol. Endocrinol. 1997; 19: 15-27Crossref PubMed Scopus (181) Google Scholar). 1,25-(OH)2D3-mediated growth inhibition also to the induction of cell S.E. T.C. Weigel N.L. Endocrinology. 2000; PubMed Scopus Google Scholar). the and of 1,25-(OH)2D3 treatment as well as the cell cycle and expression levels of cell cycle genes may the response to In this study, we that 1,25-(OH)2D3-mediated induction of p27 protein levels in LNCaP prostate cancer cells through a in the rate of p27 degradation. 1,25-(OH)2D3-mediated of p27 with a decrease in Thr187 phosphorylation of p27, the phosphorylation necessary for p27 for cyclin E-Cdk2-dependent in G1. We the that 1,25-(OH)2D3 decreased nuclear of Cdk2. Because activation of Cdk2 by the and nuclear of cytoplasmic of Cdk2 cyclin activation and the activity of this in 1,25-(OH)2D3-treated cells, the decreased Cdk2 nuclear may also to p27 degradation and may a in 1,25-(OH)2D3-mediated growth inhibition of LNCaP cells. 1,25-(OH)2D3 through its the which is a transcription inhibition of prostate cancer cells by 1,25-(OH)2D3 the however, expression is not to this effect G.J. Stapleton G.E. Hedlund T.E. Moffatt K.A. Clin. Cancer Res. 1995; 1: 997-1003PubMed Google Scholar, 11Zhuang S.-H. Schwartz G.G. Cameron D. Burnstein K.L. Mol. Cell. Endocrinol. 1997; 126: 83-90Crossref PubMed Scopus (115) Google Scholar). p27 regulation by however, occurs through effects on p27 degradation. regulation of p27 by 1,25-(OH)2D3 occurs in the cell line the p27 vitamin D response elements T. J. T. J. Biol. 1999; PubMed Scopus Google Scholar). p27 up-regulation in cells is a result of increased binding of and to the p27 to p27 Because the expression and regulation of transcription cell to 1,25-(OH)2D3 regulation of may on that may in LNCaP cells. regulation of p27 by 1,25-(OH)2D3 not with growth as S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar). The rate of p27 protein synthesis is by nuclear and the of which have in the of p27 mRNA S. A. M. A. Mol. Cell. Biol. 2000; PubMed Scopus Google Scholar, Wang G. M. R. Mol. Cell. Biol. PubMed Scopus Google Scholar, M. L. Mol. 2003; PubMed Scopus Google Scholar, M. L. 2002; PubMed Scopus Google Scholar). no for 1,25-(OH)2D3-mediated regulation of nuclear Our results p27 by 1,25-(OH)2D3 are in with studies G1 that p27 via L. PubMed Scopus Google Scholar, R. Wang Miller Endocrinology. 2003; PubMed Scopus Google Scholar, Y. H. A. Massague J. Mol. Cell. Biol. PubMed Scopus Google Scholar). p27 degradation is a and and M. P. G. M. 1995; PubMed Scopus Google Scholar, L. PubMed Scopus Google Scholar, T. T. K. K. S. J. Biol. PubMed Scopus Google Scholar, H. S. K. J.M. PubMed Scopus Google Scholar, R. S. A. R. L. Slingerland J.M. Mol. Biol. Cell. 2003; 14: PubMed Scopus Google Scholar). cells the G1 to S phase p27 levels decrease of decreased and p27 in G1. initial in p27 to cyclin In G1 and S p27 degradation is by phosphorylation of p27 at of p27 at Thr187 p27 by the which p27 and targets p27 for In LNCaP cells, 1,25-(OH)2D3 appears to regulate the phase of p27 via of Cdk2 to the to the of the vitamin D on and cells, 1,25-(OH)2D3 decreased Skp2 protein levels in LNCaP cells. the in Skp2 levels may play a role in 1,25-(OH)2D3-mediated p27 in this effect may a result of G1 Skp2 is the phase of the cell cycle C. H. M. M. M. W. J. 2000; 19: PubMed Scopus Google Scholar). the Skp2 levels for the 1,25-(OH)2D3-mediated in Thr187 phosphorylation of In decreased nuclear Cdk2 available for cyclin binding and activation result in decreased for degradation. decreased nuclear Cdk2 may the more in 1,25-(OH)2D3-mediated growth inhibition of LNCaP cells. The of Cdk2 is not well suggest a role of the in the regulation of Cdk2 C. J. Biol. PubMed Scopus Google Scholar, C. J. Biol. 2002; PubMed Scopus Google Scholar, S. A. J. G. A. 2000; 19: PubMed Scopus Google Scholar). The decrease in nuclear Cdk2 1,25-(OH)2D3 treatment may via decreased nuclear increased nuclear of Cdk2. of the cyclin the nucleus occurs via the J. R. S. J. Biol. 1999; PubMed Scopus Google Scholar). The mechanism of Cdk2 nuclear and its on the nuclear protein however, is not Cdk2 mislocalization may a in 1,25-(OH)2D3-mediated growth inhibition of LNCaP cells this to decreased cyclin G1 accumulation to decreased Cdk2 in the nucleus for cyclin binding and decreased activation of by and In addition, mislocalization of Cdk2 the phase of p27 regulation of Cdk2 may an important of the of cells the G1 to S phase of the cell We and for in and We are to Slingerland for on the We also the of and and

References

53